Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-reported outcomes of brimonidine tartrate 0.5% gel for severe facial erythema of rosacea
2012-005686-12Phase 3Completed
- Sponsor
- Galderma
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brimonidine in rosacea, Erythematotelangiectatic Rosacea (ETR), sponsored by Galderma. Started Apr 2013; status: completed.
02
Drugs
brimonidine
03
Conditions
rosaceaErythematotelangiectatic Rosacea (ETR)
Beyond the preview
Go deeper on 2012-005686-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005686-12.